Gao P, Zhang H, Zhang Q, Fang X, Wu H, Wang M, et al. Caloric Restriction Exacerbates Angiotensin II-Induced Abdominal Aortic Aneurysm in the Absence of p53. Hypertension. 2019;73:547-560 pubmed publisher

Liu Y, Xing Y, Gao X, Kuang H, Zhang J, Liu R. Obestatin prevents H2O2-induced damage through activation of TrkB in RGC-5 cells. Biomed Pharmacother. 2018;97:1061-1065 pubmed publisher

Egholm C, Khammy M, Dalsgaard T, Mazur A, Tritsaris K, Hansen A, et al. GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2016;311:H1214-H1224 pubmed publisher

McKay N, Galante D, Daniels D. Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. J Neurosci. 2014;34:16417-23 pubmed publisher

van Bloemendaal L, Ijzerman R, Ten Kulve J, Barkhof F, Konrad R, Drent M, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186-96 pubmed publisher

Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen H, Lebherz C, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 2014;63:3221-9 pubmed publisher

Ho J, Anekonda V, Thompson B, Zhu M, Curry R, Hwang B, et al. Hindbrain oxytocin receptors contribute to the effects of circulating oxytocin on food intake in male rats. Endocrinology. 2014;155:2845-57 pubmed publisher

Omar B, Andersen B, Hald J, Raun K, Nishimura E, Ahren B. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes. 2014;63:101-10 pubmed publisher

Jørgensen N, Dirksen C, Bojsen Møller K, Jacobsen S, Worm D, Hansen D, et al. Exaggerated glucagon-like peptide 1 response is important for improved ?-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62:3044-52 pubmed publisher

Kissow H, Hartmann B, Holst J, Poulsen S. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut. 2013;62:1724-33 pubmed publisher

Dozier K, Cureton E, Kwan R, Curran B, Sadjadi J, Victorino G. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides. 2009;30:1735-41 pubmed publisher

Gault V, O Harte F, Harriott P, Mooney M, Green B, Flatt P. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46:222-30 pubmed

Perfetti R, Zhou J, Doyle M, Egan J. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141:4600-5 pubmed

Baggio L, Kieffer T, Drucker D. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 2000;141:3703-9 pubmed

Edwards C, Todd J, Mahmoudi M, Wang Z, Wang R, Ghatei M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999;48:86-93 pubmed

Gunn I, O Shea D, Turton M, Beak S, Bloom S. Central glucagon-like peptide-I in the control of feeding. Biochem Soc Trans. 1996;24:581-4 pubmed